^
    RET mutation
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive
    :
    A1
    CStone Pharma Press Release - 2wk
    No biomarker
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive
    :
    A1
    RET mutation
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive
    :
    A1
    No biomarker
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive
    :
    A1
    No biomarker
    Thyroid Gland Medullary Carcinoma
    dacarbazine
    Sensitive
    :
    A2
    No biomarker
    Thyroid Gland Medullary Carcinoma
    denosumab
    Sensitive
    :
    A2
    No biomarker
    Thyroid Gland Medullary Carcinoma
    cabozantinib tablet
    Sensitive
    :
    A2
    TMB-H
    Thyroid Gland Medullary Carcinoma
    pembrolizumab
    Sensitive
    :
    A2
    RET M918T
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive
    :
    A2
    KRAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive
    :
    A2
    NRAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive
    :
    A2
    HRAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive
    :
    A2
    RET mutation
    Thyroid Gland Medullary Carcinoma
    TPX 0046
    Sensitive
    :
    C2
    RET V804*
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive
    :
    C3
    RET C634*
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive
    :
    C3
    RET M918T
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive
    :
    C3
    RET C634R
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive
    :
    C3
    RET M918T
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive
    :
    C3
    RET V804M
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive
    :
    C3
    RET M918T
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive
    :
    C3
    RET V804L
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive
    :
    C3
    RET V804M + RET M918T + RET G810 + RET Y806
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Resistant
    :
    C4
    NF1 mutation
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive
    :
    C4
    RET M918T
    Thyroid Gland Medullary Carcinoma
    everolimus + vandetanib
    Sensitive
    :
    C4
    ATM S978fs*12
    Thyroid Gland Medullary Carcinoma
    everolimus + vandetanib
    Sensitive
    :
    C4
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES